BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Cao B, Park C, Rosenblat JD, Chen Y, Iacobucci M, Subramaniapillai M, Mansur RB, Zuckerman H, Lee Y, Mcintyre RS. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. J Psychopharmacol 2019;33:1388-94. [DOI: 10.1177/0269881119874485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
2 Keks NA, Hope J, Culhane C. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Australas Psychiatry 2015;23:210-3. [DOI: 10.1177/1039856215581297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
4 Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015;29:1085-91. [PMID: 26253622 DOI: 10.1177/0269881115599387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
5 Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. Journal of Psychiatric Research 2018;101:72-9. [DOI: 10.1016/j.jpsychires.2018.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
6 Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. Neuropsychiatr Dis Treat 2016;12:951-9. [PMID: 27143896 DOI: 10.2147/NDT.S104050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
7 Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr 2017;22:348-62. [PMID: 27869048 DOI: 10.1017/S1092852916000626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
8 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015;64:88-98. [PMID: 25851751 DOI: 10.1016/j.jpsychires.2015.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
9 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre RS. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Front Psychiatry 2019;10:17. [PMID: 30766492 DOI: 10.3389/fpsyt.2019.00017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
14 Tiger M, Varnäs K, Okubo Y, Lundberg J. The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology (Berl) 2018;235:1317-34. [PMID: 29546551 DOI: 10.1007/s00213-018-4872-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
15 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
17 Choi S, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:629-38. [DOI: 10.1586/14737167.2016.1128830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Maud C. Vortioxetine in bipolar depression induces a mixed/manic switch. Australas Psychiatry 2016;24:206-7. [PMID: 26994277 DOI: 10.1177/1039856215614986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
19 Qin B, Huang G, Yang Q, Zhao M, Chen H, Gao W, Yang M. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. BMJ Open 2019;9:e033161. [PMID: 31784448 DOI: 10.1136/bmjopen-2019-033161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
21 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]